TY - JOUR
T1 - Immunometabolic alterations in lupus
T2 - where do they come from and where do we go from there?
AU - Ma, Longhuan
AU - Roach, Tracoyia
AU - Morel, Laurence
N1 - Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/10
Y1 - 2022/10
N2 - Systemic lupus erythematosus (SLE) is an autoimmune disease in which the overactivation of the immune system has been associated with metabolic alterations. Targeting the altered immunometabolism has been proposed to treat SLE patients based on their results obtained and mouse models of the disease. Here, we review the recent literature to discuss the possible origins of the alterations in the metabolism of immune cells in lupus, the dominant role of mitochondrial defects, technological advances that may move the field forward, as well as how targeting lupus immunometabolism may have therapeutic potential.
AB - Systemic lupus erythematosus (SLE) is an autoimmune disease in which the overactivation of the immune system has been associated with metabolic alterations. Targeting the altered immunometabolism has been proposed to treat SLE patients based on their results obtained and mouse models of the disease. Here, we review the recent literature to discuss the possible origins of the alterations in the metabolism of immune cells in lupus, the dominant role of mitochondrial defects, technological advances that may move the field forward, as well as how targeting lupus immunometabolism may have therapeutic potential.
UR - http://www.scopus.com/inward/record.url?scp=85138069535&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85138069535&partnerID=8YFLogxK
U2 - 10.1016/j.coi.2022.102245
DO - 10.1016/j.coi.2022.102245
M3 - Review article
C2 - 36122544
AN - SCOPUS:85138069535
SN - 0952-7915
VL - 78
JO - Current Opinion in Immunology
JF - Current Opinion in Immunology
M1 - 102245
ER -